Deletion of alloreactive AND CD4⁺ T cells in mice receiving A.SW BMT with anti-CD154. AND transgenic CD4⁺ T cells (5 × 10⁶) were adoptively transferred into B10 mice (B10-AND). These mice and control B10 mice were treated with anti-CD8, 3 Gy TBI, and anti-CD154 with either B10.A BMCs (irrelevant; B10-AND + B10.A BMT), A.SW BMCs (recognized by AND TCR; B10-AND + A.SW BMT), or sterile PBS (B10-AND). The percentage of Vα11⁺Vβ3⁺ cells in the CD4+ PBL population was assessed by 3-color FCM, and the mean (plus SD) for each respective group is shown. B10-AND mice that received B10.A BMCs had significantly higher percentages (P < .05) of AND CD4⁺ T cells at 1, 2, and 4 weeks after BMT compared with B10-AND mice that received A.SW BMCs. No significant difference was seen between mice that received irrelevant B10.A BMCs and mice that received no BMCs (individual time points not shown for these controls), whereas B10-AND mice that received A.SW BMCs showed significant deletion by 1 week after BMT. By 4 weeks after BMT, B10-AND mice that received A.SW BMCs had levels of Vα11⁺Vβ3⁺ CD4⁺ cells that were not significantly different from those in B10 mice that had not received AND CD4⁺ T cells (that received A.SW BMCs), or from those in control B10 or control A.SW mice. ^*These bars represent the average of weeks 1, 2, and 4 in each group. n.s. indicates not significant.